In conclusion, results from the current analysis comprehensively support the pre-existing evidence illustrating pCR after NAT is a sensitive biomarker and surrogate to survival in patients being treated for locally advanced HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.